

Fast Disintegrating Oral Films: A Recent Trend of Drug Delivery

Parul Saini*, Anoop Kumar¹, Pankaj Sharma², Sharad Visht¹

¹Dept. of Pharmaceutical Technology, Meerut Institute of Engineering and Technology, Meerut-250001 India.

²College of Pharmaceutical Sciences, Raj Kumar Goel Institute of Technology, Ghaziabad-201003 India.

Abstract

Oral fast disintegrating films (OFDF) is an emerging technology brings out “formulations taken without water” with quick onset of action and improved patient compliance. Oral films provide better drug utilization in by-passing the first pass metabolism, enhance drug bioavailability, mask the bitter taste of the drug and do not need water to swallow. OFDF formulations are suitable for cough, cold remedies, sore throat, allergenic conditions, nausea, pain and CNS disorders. Multivitamins, caffeine strips, snoring aid and sleeping aids are also applicable for incorporation in the oral films. The major constraints of OFDF are limited drug aqueous solubility, poor permeability and its high dose. Present article overview the advancement in the oral dosage forms, application, formulation consideration, method of preparation, evaluation, marketed product and patented technologies of oral fast disintegrating films.

*Corresponding author, Mailing address:

Parul Saini

E-mail: parulppnp@gmail.com

pankajsharma4145@gmail.com

Key words:

Patient compliance, multivitamins, low dose, high solubility, high permeability

How to Cite this Paper:

Parul Saini*, Anoop Kumar, Pankaj Sharma, Sharad Visht “Fast Disintegrating Oral Films: A Recent Trend of Drug Delivery” Int. J. Drug Dev. & Res., October-December 2012, 4(4): 80-94.

Copyright © 2012 IJDDR, Parul Saini et al.

This is an open access paper distributed under the copyright agreement with Serials Publication, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article History:-----

Date of Submission: 24-10-2012

Date of Acceptance: 04-11-2012

Conflict of Interest: NIL

Source of Support: NONE

INTRODUCTION

Despite the tremendous advancement in the drug delivery system, oral route is the most preferred route of administration and tablet and capsules are the most preferred dosage form [1-3] but now they experienced several limitations like choking and swelling discomforts in the geriatric and paediatric patients [4-5]. Among the plethora of avenues explored oral strips gain more attention as it emerging new platform for geriatric and paediatric patients [6-8].

Fast dissolving drug delivery system (FDDS) was introduced in late 1970 as the alternative to

conventional tablet, capsule and syrups especially for the geriatric and paediatric patients suffering from the dysphasia problem [9]. Fast dissolving tablets are the solid dosage form which disintegrates rapidly in the oral cavity without the need of water [10-11]. Some problems are associated with the OFDF like they are sometime difficult to carry, storing and handling (friability and fragility), these are prepared using the expensive lyophilisation method [12-13]. To overcome these problems oral films were developed, which are very popular now a days.

The concept of oral film was come from confectionary industry [4, 9]. Oral films are the recent ultra thin novel formulation of postage stamp size which contains active pharmaceutical ingredients and excipients [14]. Efficacy of API is improved as it dissolves in the oral cavity. Oral films disintegrate rapidly within seconds when it comes in contact with saliva without the need of water [15-16]. Oral fast dissolving films are useful for the geriatric and paediatric patients and also for the patients suffering from emesis, diarrhoea, allergic attacks, cough, mental disorder, bedridden patients etc [17]. Oral films are also used for local effects like local anaesthetics for oral ulcers, toothaches, cold sores and teething. Generally the shelf life of film is 2-3 years it depends on the API added to the film but films are very sensitive to environmental moisture [18].

Salivary gland is present in the oral cavity which secretes saliva [19]. Three salivary glands are present in the oral cavity i.e. parotid, submandibular and sublingual glands. Saliva is relatively less viscous as compared to GI fluids [19-20]. Saliva is mainly water which contains 1% organic and inorganic material. Saliva is a weak buffer and its pH ranges from 5.5-7. The total volume of saliva secreted from the salivary gland is 0.5-2 litres and it is the amount of saliva enough to hydrate oral mucosal dosage form [21-22].

Advantages: [23-25]

1. Oral cavity has large surface area which leads to rapid dissolution and disintegration of the oral dosage form.
2. No risk of choking
3. OFDF are solid unit dosage form so provide accurate dosing and great precision.
4. Due to pregastric absorption the bioavailability of drug is improved and fewer doses are required which improve the patient compliance.
5. OFDF's does not require water to swallow so it has better acceptability among the dysphagic patients.
6. Provide good mouth feel.
7. Oral films are flexible and less fragile as compared to OFDF's so it can easily transport handled and stored.
8. It avoid first pass metabolism as it directly absorb from the buccal mucosa and enter into the systemic circulation, side effects and dose are reduced.
9. Fast dissolving films disintegrate immediately within seconds when placed on tongue without the need of water and release one or more API.
10. Stability of the dosage form is enhanced.

Constraints of oral film: [26-28]

- High dose cannot be incorporated
- Drug should have low dose
- Should have high oral bioavailability
- Oral films have expensive packaging

Special features of oral films: [26-30]

- Ultra thin films
- Available in various size and shape
- Unobstructive
- Rapid release and fast disintegration
- Excellent mucoadhesion

Applications: [28-31]

- Oral films are preferred for local action and also to manage pain, allergies, sleeping difficulty and CNS disorders.

- Dissolvable films are feasible for topical application for wound care as analgesics or antimicrobial agents.
- Oral films are applicable to enhance the bioavailability of poorly bioavailable drugs.
- Taste masking of bitter drugs
- Dissolvable films are loaded with sensitive reagents to allow controlled release when exposed to a biological fluids or to create isolation barriers for separating multiple reagents to enable a timed reaction with a diagnostic device.

Formulation consideration: [32-33]

From the regulatory prospective all the excipients used in the formulation and development of oral films and they are regarded as safe (GRAS listed) and should be approved for use in oral pharmaceutical dosage forms. The area of oral thin films is 1-20cm² (depend on dose and drug loading containing drug). Overview on different ingredients employed in formulation of fast dissolving films is given in Table 1.

Drug (Active pharmaceutical ingredient): [15]

Different type of API can be successfully incorporated in the oral strip technology. Micronized API can improve the texture of the film and also dissolution and uniformity of the oral fast dissolving film. Different molecule can be incorporated into the delivery system. Taste of bitter drug need to be masked for that cyclodextrins or resins can be used; they prevent the direct contact of API with the saliva [34][35][36][37][38][39]. It include cough/cold remedies(antitussive, expectorants), anxiety drugs, CVS agent, sore throat, erectile dysfunction drugs, antihistamines, antiasthamatics, GI disorders, nausea, pain and CNS (antiparkinson's disease). The overview of different drugs and its properties associated with film formulations are being enlisted in table 1.

The ideal properties of drug for the development of oral strips formulation:

- a. The drug should have low dose.
- b. The dug have extensive high first pass metabolism.
- c. It should be non-bitter.
- d. It should have quick onset of action.
- e. The dug should have high solubility and high permeability (BCS class I).

Polymers [63-66]: Polymers play an important role in the film formation. Hydrophilic polymers are used in the preparation so that film can dissolve rapidly in the oral cavity and drug is delivered to the systemic circulation via dissolution when it comes in contact with the saliva in the buccal cavity [12]. The polymers can be used alone or in combination in a film to get the desired film properties. Robustness of film depends on the type and amount of polymer in the formulation. Now a day's both natural and synthetic polymers are used in the oral cavity. Natural polymers are safe, effective and devoid of side effect so more preferred than synthetic polymers.

Ideal properties of the polymers used in the oral film:[15]

1. Polymers should be non toxic and non- irritant
2. It should be non- bitter
3. Polymers should be tasteless
4. It should be devoid of leachable impurities
5. It should be inexpensive and readily available
6. It should not be an obstacle in the disintegration time
7. It should have good wetting and spreadibility property
8. It should exhibit sufficient peel, shear and tensile strength
9. It should have sufficient shelf life
10. It should not cause secondary infection in the oral cavity.

Plasticizer:^[86-97] Plasticizers are the important excipient of the oral film. It improves the flexibility and a mechanical property of the film like tensile strength and elongation and reduces the brittleness of the strip. Plasticizer significantly improves the strip properties by reducing the glass transition temperature of the polymer. A plasticizer should be selected so that it must be compatible with the drug, polymers as well as with the other excipients used in the oral film. Plasticizer can improve the flow and enhances the strength of polymer. Film cracking, splitting and peeling take place by the use of inappropriate plasticizer. Plasticizers are used in the concentration of 0–20%w/w of dry polymer weight. Different plasticizers used in the preparation of the oral films are Glycerol, propylene glycol, polyethylene glycol, dimethyl, dibutyl, diethyl phthalate, tributyl, triethyl, acetyl citrate, triacetin and castor oil.

Sweetening Agent:^[98-106] Sweeteners are the important component used in the oral films. Generally sweeteners are used for the taste masking of bitter drugs so that drugs are palatable. Sweeteners are used alone or in combination between the concentrations of 3-6%w/w. Natural as well as artificial sweeteners are used in the preparation of oral film. Natural sweeteners used are xylose, ribose, glucose, sucrose, maltose, steviosides, dextrose, fructose, liq. Glucose and isomaltose. Fructose is sweeter than sorbitol and mannitol and thus widely used as a sweetener. Artificial sweeteners used in oral films are sodium or calcium saccharine salts, cyclamates salts, Acesulfame k etc. Acesulfame k and sucralose have more than 200 & 600 times sweet. Neotame & Altitame have more than 2000-8000 times sweetening power as compared to sucrose. Dipeptide based sweeteners: Aspartame. Protein based sweetener: Thaumatin I & II.

Saliva stimulating agent:^[107-108] These are used to increase the secretion of saliva so that the oral film disintegrate and dissolve faster in the oral cavity. The

acids which are used in the preparation of food are generally used as saliva stimulators. These agents are used alone or in combination between 2-6%w/w of the oral strip. Citric acid, malic acid, lactic acid, ascorbic acid, tartaric acid are the saliva stimulating agent. Citric acid is the most preferred among them. The stimulation of salivation can be measured by comparing the amount of resting flow & stimulated flow at equal time under same condition.

Flavouring agent: Flavouring agent are those ingredients which impart flavour to any of the formulation. The perception of flavour varies from individual to individual ethnicity and personal liking. Any US-FDA approved flavour can be added to the formulation according to the choice of the individuals of different age groups. The flavours liking changes with the age as geriatric population like mint or orange flavour while young generation like fruit, raspberry, strawberry flavour. Flavouring agent should be compatible with the drug and other excipients. Flavouring agents are selected depend on their flavour impart in first few seconds and its after taste. Upto 10% of the flavouring agent can be added to the oral strip formulation. Flavouring agent can be extracted from different part of the plant like leaves, flower, fruit, bark, and seeds.

Colouring agents: Colouring agent imparts colour to the formulation. Colouring agents are selected according to the flavour. FD&C approved Colouring agents are incorporated in the oral film.

METHOD OF PREPARATION:

Oral fast dissolving film can be prepared by five methods: ^[40-62]

- Solvent casting
- Semisolid casting
- Hot melt extrusion
- Solid dispersion extrusion
- Rolling

Generally Solvent casting method is most preferred for the manufacture of fast dissolving film:

1. Solvent Casting Method: This is the most preferred method to manufacture fast dissolving film. In this method firstly water soluble ingredients are mixed in water to form viscous solution. API and remaining ingredients are dissolved in smaller amount of solution and combined with bulk by using high shear processor. Vacuum is used to remove the air entrapped. The solution formed is then cast as a film and pour the solution in a glass mould and allow the solution to dry in an oven at 45-50°C which is then cut into pieces of the desired size.

2. Semisolid Casting: This method is preferred when acid insoluble polymers are used in the preparation of oral fast dissolving film. Firstly solution of water soluble polymers is prepared. The solution is added to a solution of acid insoluble polymer. Plasticizer is added in the appropriate amount so that a gel mass is formed. The gel mass formed is then casted into the films or ribbons by using heat controlled drums. Acid insoluble polymers used to prepare films include: cellulose acetate phthalate, cellulose acetate butyrate. The thickness of the film is about 0.015-0.05 inches. Acid insoluble polymer and film forming polymer are used in the ratio of 1:4.

3. Hot melt extrusion: In this method the polymers which have low molecular weight and low viscosity are preferred. Drug is mixed with the carrier in the solid form so that granular material is formed. These granules are then dried and then introduced into the extruder. The speed of the screw should be around 15rpm so that the granules reside inside the extruder for about 3-4min. The processing temperatures should be 80°C (zone1), 115°C (zone 2), 100°C (zone 3), and 65°C (zone 4). The extrudate (T= 65°C) then pressed into a cylindrical calendar to obtain a film.

4. Solid dispersion extrusion: In this method immiscible components are taken they are then extruding with drugs. Solid dispersion is then

prepared and by means of dies the solid dispersion is shaped into films.

5. Rolling method: In this method firstly solution or suspension of drug is prepared which have certain rheological consideration. Either water or mixture of water and alcohol is mainly used as solvent. Suspension or solution containing drug is rolled on the carrier. Films are dried on the rollers and cut into desirable shapes and sizes.

EVALUATION OF THE ORAL FILM

- **Mechanical properties**

- Thickness
- Dryness/tacktest
- Tensile strength
- Percent elongation
- Young's modulus
- Tear resistance
- Folding endurance

- **Organoleptic test**

- **Swelling test**

- **Surface pH test**

- **Contact angle**

- **Transparency**

- **Assay/ content uniformity**

- **Disintegration test**

- **In-vitro dissolution test**

Thickness: A thickness of film should be measured with the help of micrometer screw gauge or calibrated digital vernier callipers. Film should be measured at five points i.e. from the centre and from all the four corners and then mean thickness is calculated. It is necessary to determine the uniformity of thickness as it is directly related to accuracy of dose in the film.

Dryness/ Tack test:^[109] Dryness is the property to measure the solvent or water content present in the film whereas tack is the tenacity with which the film adheres to any piece of paper which is pressed into contact with the strip. Eight stages of film drying

process have been recognized i.e. set-to-touch, dust-free, tack-free, dry-to-touch, dry-hard, dry-through; dry-to-recoat & dry print free. Now instruments are also available to study.

Tensile strength:^[110] It is the maximum stress applied to a point of a film at which the strip specimen breaks. It is calculated by applied load at rupture divided by the cross section area of the strip as given in the equation:

Tensile strength = Load at failure*100/ strip thickness* strip width

Percent Elongation:^[111] when stress is applied, a film sample stretches and this is referred to as strain. Strain is basically the deformation of film divided by original dimension of the sample. Generally elongation of film increases as the plasticizer content increases.

Percent elongation = $L*100/L_0$

L = Increase in length of film

L_0 = Initial length of film

Young's Modulus: Young's modulus or elastic modulus is the measure of stiffness of film. It is represented as the ratio of applied stress over strain in the region of elastic deformation as follows:

Young's Modulus = Slope*100/ Film thickness* cross head speed

Hard and brittle film demonstrates a high tensile strength and Young's modulus with small elongation.

Tear Resistance:^[112] The maximum stress or force (that is generally found near the onset of tearing) required to tear the film is recorded as the tear resistance value in Newton (or pounds -force)

Folding Endurance:^[113] Folding endurance is determined by repeated folding of the film at the same place till the film breaks. The number of times the film is folded without breaking is computed as the folding endurance value.

Organoleptic Evaluation:^[114-115] This is essential step in case of most oral formulation due to more residence time in the oral cavity. The product should possess the desired features of sweetness and flavour

which is acceptable to large mass of population. For evaluation of psychophysical evaluation of the product, special controlled human taste panels are used. In-vitro methods of utilizing taste sensors, specially designed apparatus and drug release by modified pharmacopoeial methods are being used for this purpose. Experiments using electronic tongue measurements have also been reported to distinguish between the sweetness levels in taste masking formulation.

Swelling Test:^[116-117] Simulated saliva solution is used to conduct the swelling property study. Firstly weigh all the samples of film and placed on the preweighed stainless steel wire mesh. 15ml of the saliva solution is added in the plastic container and the mesh containing film sample is submerged into it. Increase in weight of film was observed until a constant weight was observed.

The degree of swelling was calculated using parameters:

$$\alpha = \frac{wt - w_0}{w_0}$$

wt = weight of film at time t

w_0 = weight of film at time zero

Surface pH Test:^[116-117] Surface pH of the film was determined by placing the film on the surface of 1.5% w/v agar gel followed by placing pH paper (pH range 1-11) on films. The change in the color of pH paper was observed and reported.

Contact Angle: Contact angle are measured by Goniometer (AB Lorentz and wettre, Germany) at room temperature. Take a dry film and place a drop of distilled water on the surface of the dry film. Images of water droplet were recorded with in 10 sec of deposition by means of digital camera. The contact angle was measured on both side of drop and average is taken.

Transparency:^[118-119] The transparency of the films can be determined using a simple UV spectrophotometer. Cut the film in the rectangular shape and placed inside the spectrophotometer cell. Determine the transparency of the film at 600nm.

The transparency of the film was calculated as follows:

$$\text{Transparency} = (\log T_{600})/b = -\epsilon C$$

Where, T_{600} = transmittance at 600nm

b = film thickness (mm)

C = concentration

Assay/ Content Uniformity: This is determined by any standard assay method described for the particular API in any of the standard pharmacopoeia. Content uniformity is determined by estimating the API content in individual strip. Limit of content uniformity is 85-115%.

Disintegration Test:^[120-121] The disintegration time limit is 90sec or less. Although no official guidelines is available for oral strips. Pharmacopoeial disintegrating test apparatus may be used for the study. Typical disintegration time for oral strip is 5-30sec.

In-vitro Dissolution test:^[122-123] Dissolution testing can be performed using the standard basket or paddle apparatus described in any of the pharmacopoeia. The dissolution medium will essentially be selected as per the sink conditions and highest dose of the API. Many times the dissolution test can be difficult due to tendency of the strip to float onto the dissolution medium when the paddle apparatus is employed.

Table 1: Generalized Details of Different Ingredients of Oral Film

| S. No | INGREDIENTS | AMOUNT(w/w) |
|-------|----------------------------|-------------|
| 1 | Drug(API) | 5-30% |
| 2 | Water soluble polymer | 45% |
| 3 | Plasticizer | 0-20% |
| 4 | Saliva stimulating agent | 2-6% |
| 5 | Surfactant | Q.S. |
| 6 | Sweetening Agent | 3-6% |
| 7 | Flavours, Colours, Fillers | Q.S |

Table 2: Rationale of fast dissolvable films formulation of selected drug

| DRUG | CATEGORY | DOSE (mg) | SOLUBILITY | PROBLEM ASSOCIATED |
|--------------------------------|-----------------------------------------------|-----------|-----------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|
| Salbutamol sulphate | Antiasthmatic | 6-16 | Soluble 1 in 4 of water; slightly soluble in ethanol, chloroform, and ether | High first pass metabolism, bioavailability 50% |
| Montelukast sodium | Antiallergic | 5-10 | freely soluble in ethanol, methanol and water and practically insoluble in acetonitrile | Protein binding 99%, bioavailability 65% |
| Levocirtrazine dihydrochloride | 5-HT Antagonist | 5 | Soluble in water | Low bioavailability, first pass metabolism |
| Ropinirole Hydrochloride | Antiparkinsonism drug | 3-9 | Soluble in water | Bioavailability 50-55%, bitter drug |
| Triclosan | Antimicrobial agent | 3.5 | Practically insoluble in water; very soluble in most organic solvents | Bitter taste, insoluble in water |
| Sertraline | Antidepressant drug | 4 | Slightly soluble in water and freely soluble in ethanol | Bioavailability 45%, low solubility, extensive first pass metabolism |
| Ondansetron hydrochloride | Antiemetic drug | 8-16 | Soluble in aq. Solutions, solubility decreases with pH | Extensive first pass metabolism, 60% bioavailability, short half life i.e 5hr |
| Rizatriptan Benzoate | 5-HT Agonist | 5-10 | | Bioavailability 40-45%, extensive first pass effect |
| Valsartan | Antihypertensive | 80-160 | Slightly soluble in water, soluble in ethanol and methanol | Bioavailability 23%, protein binding 94-97% |
| Verapamil | Antihypertensive, antianginal, antiarrhythmic | 40-120 | Practically insoluble in water, freely soluble in lower alcohol, acetone, ethyl acetate, chloroform, soluble in benzene and ether | 20% bioavailability, 90% protein binding of drug, extensive first pass metabolism |
| Domperidone | Antiemetic | 10-20 | Low water solubility, soluble in acidic pH | Protein binding is 91-93% |
| Ivabradine Hydrochloride | Antianginal drug | 5-10 | Soluble in water | Extensive first pass metabolism, short half life of 2hr, 40% bioavailability |
| Citalopram hydrobromide | Antidepressant | 20-60 | Sparingly soluble in water, soluble in ethanol | Bitter drug, low solubility |
| Dexamethsone | Antiemetic | 0.5-9 | Insoluble in water, soluble in ethanol, chloroform, acetone, sparingly soluble in methanol, slightly soluble in ether | Solubility problem, 65% drug excreted in urine in 24hr |
| Ambroxol hydrochloride | Mucolytic agent | 30 | Soluble in water | Extensive first pass effect |
| Meclizine HCl | Antiemetic agent | 25-100 | Poorly water soluble | Bitter drug, solubility problem |

Table 3: Overview of different ingredients employed in formulating of fast dissolving films

| Drug | Polymer | Plasticizer | Super Disintegrant | Sweetener | Method of preparation | Property improved |
|--------------------------------|--------------------------------------------------------------------|------------------------------------------------------------|---------------------------------------|-------------------------------------------|----------------------------|-----------------------------------------------------------------------------------------------|
| Salbutamol sulphate | HPMC, HPC, Sodium Alginate | - | - | Aspartame | Solvent evaporation method | Taste masking of bitter drug |
| Montelukast sodium | HPC, HPMC | Glycerine | Cross povidone, croscarmellose sodium | Sucrose | Solvent casting method | Maximum drug release and it follow first order kinetics |
| Levocirtrazine dihydrochloride | Eudragit EPO, HPMC E 5 LV, and PVA | Glycerin, dibutyl phthalate, propylene glycol, and PEG 400 | - | Mannitol, Aspartame | Solvent casting method | Increase in % drug release |
| Ropinirole Hydrochloride | Pullulan gum | PEG 400 | - | Sucralose, Aspartame | Solvent casting method | Increase in % drug release using pullulan gum |
| Triclosan | HPMC (Methocel E3, E5, E15 premium LV) | pylene glycol | - | Aspartame, mannitol, sorbitol and xylitol | Solvent casting method | Improve solubility of poorly water soluble drug |
| Sertraline | polyvinyl pyrrolidone, Carbopol 934P | Propylene glycol or PEG 400 | - | Mannitol, sodium saccharin | Solvent casting method | Improvement of solubility, bioavailability and increase in % drug release |
| Ondansetron Hydrochloride | polyvinylalcohol, polyvinyl pyrrolidone, Carbopol 934P | Propylene glycol or PEG 400 | - | Mannitol, sodium saccharin | Solvent casting method | Improve patient compliance, better bioavailability, taste masking of bitter drug |
| Rizatriptan Benzoate | HPMC E 15, maltodextrin | - | Sodium starch glycolate | Aspartame, mannitol | Solvent casting method | Improve drug release, patient compliance, better bioavailability |
| Valsartan | HPMC (E5, K4M, 50cps), Propylene glycol, hupu gum, guar gum | PEG | - | Sorbitol | Solvent casting method | Taste masking of drug, improve drug solubility and bioavailability |
| Verapamil | HPMC E6, maltodextrin | Glycerol | - | Aspartame | Solvent casting method | Improve bioavailability, bypass first pass metabolism |
| Domperidone | PVA | Glycerine | - | mannitol | Solvent casting method | Quick onset of action |
| Ivabradine Hydrochloride | Hydroxy propylmethyl cellulose E5 | PEG 400 | Crospovidone, SSG | Aspartame | Solvent casting method | Bypass first metabolism |
| Amlodipine Besylate | Sodium Alginate | Glycerol | SSG | Aspartame | Solvent casting method | Enhanced dissolution rate, taste masking, and better patient compliance and effective therapy |
| Citalopram hydrobromide | HPMC E5 | Proylene glycol | - | Sorbitol | Solvent casting method | Quick onset of action, improve patient compliance |
| Cetirizine Hydrochloride | Pullulan gum | PEG 400 | - | Aspartame, Sucralose | Solvent casting method | Taste masking, improve mechanical properties of film |
| Dicyclomine Hydrochloride | PVA., HPMC-15, HPMC-50: Eudragid, HPMC-15:PVA | PEG 400 | - | Aspartame | Solvent casting method | Better therapeutic efficacy, increase bioavailability, taste masking of drug |
| Metaclopramide Hydrochloride | HPMC E6, SCMC, | Glycerol | Sodium bicarbonate | Saccharine sodium | Solvent casting method | Patient compliance, physical property improve |
| Telmisartan | HPMC E5, HPMC50cps, HPMC K4M | Propylene glycol | - | sorbitol | Solvent casting method | Enhance solubility, bypass first pass metabolism |
| Tianeptine Sodium | NG73, HPMC, Hydroxy ethyl cellulose, PVP K 90, RS78o, maltodextrin | PEG | - | - | Solvent casting method | Enhance compliance and convenience by elderly and pediatric patients |
| Valdecoxib | HPMC, Eudragit EPO | Glycerol | - | Aspartame | Solvent casting method | Improve drug release, mask bitter taste |

Table 4: Characteristics of Some Natural Polymers Employed In Oral Films and Their Applications

| Polymer | Film Forming Ability | Viscosity | Melting Point | Solubility | Application |
|-----------------|-----------------------------------------|-------------------------------------------------------------------------------------------------------|----------------|-------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Pullulan gum | It form flexible film in 5-25% solution | It is 100-180mm ² /s viscous at 10%w/w, and at 30°C | 107°C | Soluble in hot and cold water | Used in food industry to provide bulk and texture, as plasma expander in replacement of Dextran, for coating of immediate release tablets, for preparation of capsule shell |
| Sodium Alginate | It have film forming capacity | Typically, a 1% w/v aq. Sol ⁿ , at 208C, will have a viscosity of 20–400 mPa s (20–400 cP) | >300°C (572°F) | Slowly soluble in water and form colloidal solution | Stabilizing agent; suspending agent; tablet and capsule disintegrant; tablet binder; viscosity increasing agent |
| Pectin | It have film forming capacity | - | 152°C | Soluble in water; insoluble in ethanol (95%) and other Organic solvents | Used as gel forming agent for sustained release drugs, used as adsorbant, emulsifying agent, stabilizing agent, bulk forming agent for the preparation used for management of diathorrea and constipation |
| Gelatin | Very good film forming capacity | 4.3-4.7mPa s for a 6.67%w/v aq. Solution at 60° | - | Soluble in glycerin, acid, alkali. Swell in water and softens. Soluble in hot water | Used in the preparation of hard and soft gelatin capsule, in implantable delivery system, in microcapsulation of drugs, used topically in wound dressing. |
| Malto Dextrin | Very good film forming capacity | Less than 20 mPa s for a 20% w/v aqueous solution | - | Swells in water and softens. Soluble in hot water | Used as binder and diluent in tablet, carrier in spray dried redispersible emulsion, used as carbohydrate source in oral nutritional suppliment, used in confectionary and food product. |

Table 5: Synthetic Polymers Used In Oral Films

| Polymer | Film Forming Ability | Viscosity | Melting Point | Solubility | Application |
|---------------------------------|-------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|-------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Hydroxy propyl cellulose | It has a good film forming property and 5%w/w solution is generally used for film coating | The viscosity of solutions ranges from 75 mPa s– 6500 mPa s | It softens at 130 °C; chars at 260–275 °C | It is freely soluble in water, soluble in many cold and hot polar organic solvents | Used as a tablet binder, in preparation of modified release dosage form, microcapsules, As thickening agent in the oral and topical Formulations. Due to its nonionic nature, as emulsifier in the cosmetic formulations. |
| Hydroxy propyl methyl cellulose | It has a film forming ability in 2–20%w/w concentrations | Viscosity of various grades ranges from 3 mPa s– 100,000 mPa s | Browns at 190–200 °C glass transition temperature is 170–180 °C | Soluble in cold water, forming a viscous colloidal solution, insoluble in chloroform, ethanol | Used as a tablet binder, film coating agent, film forming agent and as a matrix for use in extended release formulations, suspending and thickening agent, emulsifier, suspending agent and stabilizing agent in gels and ointments, adhesive in plastic bandage and as a wetting agent in contact lenses |
| Sodium carboxy methyl cellulose | Good film forming property | Aqueous 1% w/v solutions with viscosities of 5–2000 mPa s | Browns at approximately 2278C, and chars at approximately 2528C. | Practically insoluble in acetone, ethanol (95%), ether and toluene | Coating agent; stabilizing agent; suspending agent; tablet and capsule disintegrant; tablet binder; viscosity-increasing agent; water-absorbing agent |
| Polyvinyl alcohol | Good film forming property | High viscosity 40.0–65.0, Medium viscosity 21.0–33.0, Low viscosity 4.0–7.0 | 228°C for fully hydrolyzed grades; 180-1908°C for partially hydrolyzed grades | Soluble in water; slightly soluble in ethanol (95%); insoluble in organic solvents | Coating agent; lubricant; stabilizing agent; viscosity-increasing agent |
| Poly ethylene oxide | Good film forming property | WSR N-10 30–50 | 65-70°C | Polyethylene oxide is soluble in water and a number of common organic solvents such as acetonitrile, chloroform, and methylene chloride. | Mucoadhesive; coating agent; tablet binder; thickening agent. |
| Carboxy methyl cellulose | Good film forming property | The 1%w/w aqueous solution has viscosity in the range of 5–13,000 mPa s | Browns at 227 °C and chars at 252 °C. | It is easily dispersed in water to form a clear or colloidal solution | Used as a viscosity increasing agent, stabilizer for preparation of suspensions and emulsions, utilized as a binder or disintegrant, cryoprotective agent. It is reported for use in combination with other film forming polymers for preparation of oral films |
| Starch and modified starch | Modified starches have a property to form quick dissolving films. | 2%w/v aqueous dispersion of starch provides 13 mPa s viscosity. | It decomposes at 250 °C | Soluble in water and ethanol. It swells in water by about 5 to 10% at 37 °C | Starch is used as binder, diluents and disintegrate, for coating of immediate release dosage forms, used in the treatment of dehydration. |
| Kollocoat | Kollocoat have good film forming property, it form transparent film | <15 mPa s for Kollocoat MAE 100 P and Kollocoat MAE 30 DP | 209°C | >50% in water | Film-forming agent; tablet binder; tablet diluents |

Table 6: Different flavours used in the oral strip are:

| | |
|-----------------------|-----------------------------------------------------------|
| Oils | peppermint oil, cinnamon oil, spearmint oil, nutmeg oil |
| Fruit flavours | Apple, raspberry, cherry, strawberry, pineapple |
| Salt | Butterscotch, maple, apricot, peach, vanilla, mint, anise |
| Bitter | Wild cherry, walnut, chocolate, mint, anise |
| Sweet | Vanilla, fruit, berry |
| Sour | Citric flavour, root bear, raspberry |

Table 7: Marketed Product of Oral Film

| Oral film | Active ingredients | Manufacturer/ marketed | Category |
|---------------------------------|----------------------|----------------------------|----------------------|
| Klonopin Wafers | Clonazepam | Solvay pharmaceuticals | Antianxiety |
| Listerine cool mint pocket paks | Cool Mint | Pfizer | Mouth freshener |
| Benadryl | Diphenhydramine HCl | Pfizer | Antiallergic |
| Listerine | cool mint | Pfizer | Mouth freshener |
| Chloraseptic | Benzocaine/ Menthol | Prestige | Sore throat |
| Gas-X | Simethicone | Novartis | Anti Flatuating |
| Sudafed PE | Phenylephrine | Wolters Kluwer Health Inc. | Relieving Congestion |
| Supress ^R | Menthol | InnoZen ^R , Inc | Cough suppressants |
| Triaminic | Diphenhydramine HCl | Novartis | Anti allergic |
| Theraflu | Dextromethorphan HBR | Novartis | Cough suppressants |

References:

- 1) Samita Gauri, Gaurav Kumar. Fast Dissolving Drug Delivery and its Technologies. *www.thepharmajournal.com*. 2012;1(2): 34-39.
- 2) Saurabh R, Malviya R, Sharma PK. Trends in Buccal Film: Formulation Characteristics. *Recent Studies and Patents. European Journal of Applied Sciences*. 2011; 3(3):93-101.
- 3) Priya Y D, Chaudhary Y A, Murthy T E G K, Seshagiri B. Approaches for taste masking of bitter drugs: a Review. *Journal of Advances in Drug Research*. 2011; (2): 58-67.
- 4) Subash vijaya kumar, Basani gavaskar, Guru Sharan, Y.madhusudan rao. Overview on fast dissolving films. *International journal of pharmacy and pharmaceutical sciences*. 2010; 2(3): 29-33
- 5) Committee for Medicinal Products for Human Use, European Medicines Agency EMEA, Reflection paper: formulation of choice for the pediatric population, Sep. 2006.
- 6) Aggarwal Jyoti, Singh Gurpreet, Saini Seema, Rana A C. Fast dissolving films: A novel approach to oral drug delivery. *International research journal of pharmacy*, 2011; 2(12): 69-74.
- 7) Goel Honey, Rai Parshuram, Rana Vikas, Tiwary K Ashok. Orally disintegrating systems: Innovations in formulation and technology. *Recent patents on drug delivery & formulation*. 2008; 2: 258-274.
- 8) Bhowmik Debjit, Chiranjib B, Krishnakanth, pankaj, Margret R Chandira. Fast dissolving tablet: An overview journal of chemical and pharmaceutical research. 2009;1(1):163-177.
- 9) Alpesh R Patel, Dharmendr S Prajapati, Jignyash A Raval. Fast dissolving films (FDSs) as a newer venture in fast dissolving dosage forms. *International journal of drug development and research*; 2010; 2(2): 232-246.
- 10) Arunachalam A, Karthikeyan M, kumar S A, Konam K, Prasad P H, Sethuraman S, Manidipa S. Fast Dissolving Drug Delivery System: A Review. *Journal of Global Trends in Pharmaceutical Sciences*. 2010; 1(1): 92-110.
- 11) Mudgal vinod kumar, Sethi pooja, Kheri Rajat, Saraogi GK, Singhai AK. Orally disintegrating tablets: A review. *International research journal of pharmacy*. 2011; 2(4): 16-22.
- 12) V.Dinesh kumar, Ira Sharma and Vipin Sharma. A comprehensive review on fast dissolving tablet

- technology. *Journal of Applied Pharmaceutical Science*. 2011; 01(05): 50-58.
- 13) Adamo Fini, Valentina Bergamante, Gian Carlo Ceschel, Celestino Ronchi, Carlos Alberto Fonseca de Moraes. Fast dispersible/slow releasing ibuprofen tablets. *European Journal of Pharmaceutics and Biopharmaceutics*; 2008;69: 335-341.
 - 14) Arun Arya, Amrisha Chandra, Vijay Sharma, Kamla Pathak. Fast Dissolving Oral Films: An Innovative drug delivery System and Dosage Form. *International Journal of ChemTech Research*. 2010; 2(1): 576-583.
 - 15) R.P. Dixit, S.P. Puthli. Oral strip technology: Overview and future potential. *Journal of Controlled Release*. 2009; 139: 94-107.
 - 16) Dahiya Meenu, Saha Sumit Shahiwal, Aliasgar F. A Review on Mouth Dissolving Films Current Drug Delivery. 2009; 6(5): 469-476(8).
 - 17) Sheetal Malke, Supriya Shidhaye, Jignesh Desai, Vilasrao Kadam. Oral Films - Patient Compliant Dosage Form for Paediatrics. *The Internet Journal of Pediatrics and Neonatology*. 2010; 11(2) DOI: 10.5580/44e.
 - 18) Malke M, Shidhaye & V J Kadam. Formulation and evaluation of Oxacarbazine fast dissolving tablets. *Indian journal of pharmaceutical sciences*. 2007; 69(2): 211-214.
 - 19) Tabak L A, CMJ Levine, I D Mandel and SA Ellison. Role of salivary mucin in the protection of Oral cavity. *J. Oral Pathology and Med.*, 11:1-17.
 - 20) Rathbone M, B Drummond and I Tucker. Oral cavity as a site for systemic drug delivery, advanced drug delivery reviews. 1994; 13(1-2):1-22.
 - 21) Shojaei AH. Buccal mucosa as a route for systemic drug delivery: a review. *Journal of pharmacy and pharmaceutical sciences*; 1998, 1(1): 15-30.
 - 22) Harris D and J R Robinson. Drug delivery via the mucous membranes of the oral cavity. *Journal of pharmaceutical Sciences*. 1992, 81: 1-10.
 - 23) Kulkarni A S, Deokule H A, Mane M S and Ghadge D M. Exploration of different polymers for use in the formulation of oral fast dissolving strips. *Journal of current pharmaceutical research*. 2010; 2(1): 33-35.
 - 24) Swapnil patil, Paresh R mahaparale, Madhavi A shivnikar, Shradha S Stiwari, Ketan V Pawar, Prashant N Sane. Fast dissolving oral films: an innovative drug delivery system. *International journal of drug discovery and medical research*; 2010; 1(1); 39-43.
 - 25) Bradoo R. Fast Dissolving Drug Delivery Systems. *JAMA India* 2001; 4 (10): 27-31.
 - 26) Bhupinder Bhyana, sarita Jangra, Mandeep Kaur, harmanpreet singh. Orally fast dissolving films: Innovation in formulation and technology. *International journal of pharmaceutical sciences review and research*. 2011; 9(2):50-57.
 - 27) Dipika parmar, Upendra patel, Bhavin Bhimni, Aditi Tripathi, Dhiren Daslaniya, Ghanshyam patel. Orally fast dissolving films as dominant dosage form for quick release. *International journal of pharmaceutical research and bioscience*. 2012; 1(3):27-41.
 - 28) Sweta Kalyan, Mayank bansal. Recent trends in the development of oral dissolving films. *International journal of pharm Tech research*. 2012; 4(2): 725-735.
 - 29) Vishwkarma DK, Tripathi AK, Yogesh P and Maddheshiya B. Review article on mouth dissolving films. *Journal of global pharma Technology*. 2011; 3(1):1-8.
 - 30) Rathi Varun, Senthil V, Kammili Lavanya, Hans Ritu. A brief review on oral film technology. *International journal of research in ayurveda and pharmacy*. 2011; 2(4): 1138-1147.
 - 31) M.D. Nehal Siddiqui, Garima Garg and Pramod Kumar Sharma. A Short Review on a Novel Approach in Oral Fast Dissolving Drug Delivery System and Their Patents. *Advances in Biological Research* 5 (6): 291-303, 2011.
 - 32) Peppas N A and P A Buri. Surface interfacial and molecular aspects of polymer bioadhesion on soft tissues. *J controlled release*. 1985; 2: 257-275.
 - 33) Tabak LA, MJ Levine, ID Mandel and SA Ellison. Role of salivary mucins in the protection of oral cavity. *J oral pathology and Med.*, 1982; 11: 1-17.
 - 34) H. Sohi, Y. Sultana, R.K. Khar, Taste masking technologies in oral pharmaceuticals: recent

- developments and approaches, Drug Dev. Ind. Pharm. 2004, 30; 429-448.
- 35) J. Szejtli, L. Szente, Elimination of bitter, disgusting tastes of drugs and foods by cyclodextrins, Eur. J. Pharm. Biopharm. 2005; 61 (3):115-125.
 - 36) C. Agresti, Z. Tu, C. Ng, Y. Yang, J.F. Liang, Specific interactions between diphenhydramine and α -helical poly(glutamic acid)-a new ion-pairing complex for taste masking and pH-controlled diphenhydramine release, Eur. J. Pharm. Biopharm. 2008;70(1): 226-233.
 - 37) R. Agarwal, R. Mittal, A. Singh, Studies of ion-exchange resin complex of chloroquine phosphate, Drug Dev. Ind. Pharm. 2000; 26: 773-776.
 - 38) H. Suzuki, H. Onishi, Y. Takahashi, M. Iwata, Y. Machida, Development of oral acetaminophen chewable tablets with inhibited bitter taste, Int J Pharm. 2003 251(1-2) 123-132.
 - 39) H. Sugao, S. Yamazaki, H. Shiozawa, K. Yano, Taste masking of bitter drug powder without loss of bioavailability by heat treatment of wax-coated microparticles, J. Pharm. Sci. 1998; 87: 96-100.
 - 40) NL Prasanthi, C Sowmya Krishna, M Eswar Gupta, SS Manikiran, N Rama Rao. Design and Development of Sublingual Fast Dissolving Films for an Antiasthmatic Drug. Scholars Research Library Der Pharmacia Lettre, 2011, 3(1): 382-395.
 - 41) Vijaykumar ghorwade, Ajaykumar patil, Asha Hullale. Fast dissolving films: a novel approach for the delivery of montelukast sodium. International journal of pharmacy and pharmaceutical sciences, 2012; 4(2): 228-232.
 - 42) J Gunjan Patel, A Darshan Modi. Formulation, optimization and evaluation of levocetirizine dihydrochloride oral thin strip. Journal of pharmacy and bioallied sciences 2012; 4(5): 35-36.
 - 43) Mital S. Panchal, Hiren Patel, Aarti Bagada, Dr. K.R.Vadalia. Formulation and Evaluation of Mouth Dissolving Film of Ropinirole Hydrochloride by Using Pullulan Polymers. International Journal of Pharmaceutical Research & Allied Sciences. 2012; (3): 60-72.
 - 44) Aditya Dinger and Mangal Nagarsenker. Formulation and Evaluation of Fast Dissolving Films for Delivery of Triclosan to the Oral Cavity. AAPS PharmSciTech; 2008; 9(2): 349-356.
 - 45) Apoorva Mahajan. Formulation & Evaluation of fast dissolving Buccal films of Sertraline. International Journal of Drug Development & Research. 2012; 4(1): 220-226.
 - 46) M Koland, VP Sandeep, and NR Charyulu. Fast Dissolving Sublingual Films of Ondansetron Hydrochloride: Effect of Additives on *in vitro* Drug Release and Mucosal Permeation. J Young Pharm. 2010; 2(3): 216-222.
 - 47) Bhyan Bhupinder, Jangra Sarita. Formulation and evaluation of fast dissolving sublingual films of Rizatriptan Benzoate. Int. J. Drug Dev. & Res., Jan-March 2012, 4 (1): 133-143.
 - 48) Rajesh Kaza, R. Arun Kumar. Design and Characterization of Fast Dissolving Films of Valsartan. International Journal of Innovative Pharmaceutical Research. 2012,3(2),212-219.
 - 49) S. Kunte and P. Tandale. Fast dissolving strips: A novel approach for the delivery of verapamil. J Pharm Bioallied Sci. 2010; 2(4): 325-328.
 - 50) Pratikkumar Joshi, Harsha Patel, Vishnu Patel, Rushi Panchal. Formulation development and evaluation of mouth dissolving film of domperidone. Journal of pharmacy and bioallied sciences; 2012; 4(5): 108-109.
 - 51) Ravneet Kaur, Rajni Bala. Formulation And Evaluation Of Ivabradine Hydrochloride Fast Dissolving Film. Journal of Pharmacy Research 2012,5(6),3327-3330.
 - 52) B. Rubia Yasmeen, S. Firoz, Y. Chandra Mouli, A. Vikram, B. Mahitha, U. Aruna. Preparation and evaluation of oral fast dissolving films of citalopram hydrobromide. International Journal of Biopharmaceutics. 2012; 3(2): 103-106.
 - 53) Minako Nishigakia, Kana Kawaharab, Masahito Nawac, Manabu Futamura, Misao Nishimurad, Katsuhiko Matsuura, Kiyoyuki Kitaichi, Yoshihiro Kawaguchic, Tadao Tsukiokad, Kazuhiro Yoshidac, Yoshinori Itoha. Development of fast dissolving oral film containing dexamethasone as antiemetic medication: Clinical usefulness. International Journal of Pharmaceutics 2012;424: 12- 17.

- 54) Nidhi P. Sapkal, Vaishali A. Kilor, Anwar S. Daud, Minal N. Bonde. Development of fast dissolving oral thin films of ambroxol hydrochloride: Effect of formulation variables. *Journal of Advanced Pharmaceutical Research*. 2011; 2(2), 102-109.
- 55) Gupta M.M, Patel Mitul G and Madhulika Kedawa. Enhancement of dissolution rate of rapidly dissolving oral film of meclizine hydrochloride by complexation of Meclizine hydrochloride with β -cyclodextrine. 2011; 01(09): 150-153.
- 56) Shelke PV, Dumbare AS, Gadhave MV, Jadhav SL, Sonawane AA, Gaikwad DD. Formulation and evaluation of rapidly disintegrating film of amlodipine besylate. *Journal of drug delivery & therapeutics*. 2012; 2(2): 72-75.
- 57) Renuka Mishra and Avani Amin. Formulation and Characterization of Rapidly Dissolving Films of Cetirizine hydrochloride using Pullulan as a Film Forming Agent. *Indian Journal of Pharmaceutical Education and Research* .2011;45(1): 71-77.
- 58) Alka Tomar, Kiran Sharma, Nitesh S Chauhan, Ashu Mittal, Umakant Bajaj. Formulation and Evaluation of Fast Dissolving Oral Film of Dicyclomine as potential route of Buccal Delivery. *Int. J. Drug Dev. & Res.*, April-June 2012, 4 (2): 408-417.
- 59) S Raju, P Sandeep Reddy, V Anirudh Kumar, A Deepthi, K Sreeramulu Reddy, PV Madhava Reddy. Flash release oral films of metoclopramide hydrochloride for pediatric use: Formulation and in-vitro evaluation *Journal of Chemical and Pharmaceutical Research*. 2011, 3(4):636-646.
- 60) Rajesh Kaza, S Rahul Ali, R Arun Kumar. Fabrication and Evaluation of Telmisartan Rapidly Dissolving films. *International Journal of Innovative Pharmaceutical Research*. 2012; 3 (2), 220-227.
- 61) Doaa Ahmed El-Setouhy, Nevine Shawky Abd El-Malak. Formulation of a Novel Tianeptine Sodium Orodispersible Film. *AAPS PharmSciTech*. 2010;11(3):1018- 1025.
- 62) Renuka Sharma, RK Parikh, MC Gohel, MM Soniwala. Development of taste masked film of valdecoxib for oral use. *Indian journal of pharmaceutical sciences*. 2007; 69(2): 320-323.
- 63) Kulkarni A S, Deokule HA, Mane MS, Ghadge DM. Exploration of different polymers for use in the formulation of oral fast dissolving strips. *Journal of Current Pharmaceutical Research*. 2010; 2(1): 33-35.
- 64) Garsuch V, Breikreutz J. Comparative investigations on different polymers for the preparation of fast-dissolving oral film. *J Pharm Pharmacol*. 2010; 62(4):539-45.
- 65) Priyanka Nagar, Iti Chauhan, Mohd Yasir. Insights into Polymers: Film Formers in Mouth Dissolving Films. *Drug Invention Today*, 2011, 3(12), 280-289.
- 66) C. Corniello. Quick dissolving strips: from concept to commercialization. *Drug Del. Technol*. 2006; 6(2):68-71.
- 67) Leduy A, Zajic JE, Luong JHT, Pullulan In: *Encyclopedia of Polymer Science and Engineering*, 2nd ed., Wiley & Sons, New York, 1988, 650.
- 68) Fraser CG, Jennings HJ, A Glucan from *Tremella mesenterica* NRRL-Y6158. *Canadian J of Chemistry*. 1971; 49:1804-1807.
- 69) Delben F, Forabosco A, Guerrini M, Liut G, Torri G, Pullulans produced by strains of *Cryphonectria parasitica*-II. Nuclear magnetic resonance evidence. *Carbohyd. Polym*, 2006;63:545-554.
- 70) Chi Z, Zhao S, Optimization of medium and new cultivation conditions for pullulan production by a new pullulan-producing yeast strain. *Enzyme and MicrobialTechnology*, 2003; 33:206-211.
- 71) Wu Y, Weller CL, Hamouz F, Cuppett S, Schnepf MJ, *Food Sci.*, 2001, 66, 486-93.
- 72) FAO Corporate Document Repository. A Guide to the seaweed industry. <http://www.fao.org/docrep/006/y4765e/y4765e08.htm>.
- 73) Raymond C Rowe, Paul J Sheskey, Marian E Quinn. Sodium Alginate. *Handbook of pharmaceutical excipients*. Pharmaceutical press, London. 2009;6: 622-624.
- 74) Raymond C Rowe, Paul J Sheskey, Marian E Quinn. Pectin. *Handbook of pharmaceutical excipients*. Pharmaceutical press, London, 2009; 6: 478-479.
- 75) Raymond C Rowe, Paul J Sheskey, Marian E Quinn. Gelatin. *Handbook of pharmaceutical excipients*. Pharmaceutical press, London. 2009; 6: 278-289.

- 76) Raymond C Rowe, Paul J Sheskey, Marian E Quinn. Maltodextrin. Handbook of pharmaceutical excipients. Pharmaceutical press, London.2009;6: 418-420.
- 77) Raymond C Rowe, Paul J Sheskey, Marian E Quinn. Hydroxy propyl cellulose. Handbook of pharmaceutical excipients. Pharmaceutical press, London.2009;6:317-321.
- 78) Raymond C Rowe, Paul J Sheskey, Marian E Quinn. Hydroxy propyl methyl cellulose. Handbook of pharmaceutical excipients. Pharmaceutical press, London. 2009;6:326-329.
- 79) Banker G et al. Evaluation of hydroxypropyl cellulose and hydroxypropyl methyl cellulose as aqueous based film coatings. Drug Dev Ind Pharm 1981; 7: 693-716.
- 80) Raymond C Rowe, Paul J Sheskey, Marian E Quinn. Carboxy methyl cellulose sodium. Handbook of pharmaceutical excipients. Pharmaceutical press.2009;6:118-121.
- 81) Raymond C Rowe, Paul J Sheskey, Marian E Quinn. Polyvinyl alcohol. Handbook of pharmaceutical excipients. Pharmaceutical press, London.2009; 6: 564-565.
- 82) Raymond C Rowe, Paul J Sheskey, Marian E Quinn. Polyethylene oxide. Handbook of pharmaceutical excipients. Pharmaceutical press, London.2009; 6: 522-524.
- 83) Raymond C Rowe, Paul J Sheskey, Marian E Quinn. Carboxy methylcellulose. Handbook of pharmaceutical excipients. Pharmaceutical press, London. 2009; 6:522-524.
- 84) Raymond C Rowe, Paul J Sheskey, Marian E Quinn. Starch and modified starch. Handbook of pharmaceutical excipients. Pharmaceutical press, London, 2009;6:685-695.
- 85) G.S. Banker, Film coating theory and practice, J. Pharm. Sci. 1966;55:81-89.
- 86) L.M.E. McIndoe, Castor oil, in: R.C. Rowe, P.J. Sheskey, S.C. Owen (Eds.), Handbook of Pharmaceutical Excipients, Pharmaceutical press.2006: 128-130.
- 87) R.T. Guest, Dibutyl phthalate, in: R.C. Rowe, P.J. Sheskey, S.C.Owen (Eds.), Handbook of Pharmaceutical Excipients, Pharmaceutical press. 2006:234-235.
- 88) S.W. Kennedy, Dibutyl sebacate, in: R.C. Rowe, P.J. Sheskey, S.C. Owen (Eds.), Handbook of Pharmaceutical Excipients, Pharmaceutical press. 2006: 236-237.
- 89) R.T. Guest, Diethyl phthalate, in: R.C. Rowe, P.J. Sheskey, S.C.Owen (Eds.), Handbook of Pharmaceutical Excipients, Pharmaceutical press. 2006: 240-241.
- 90) J.C. Price, Polyethylene glycol, in: R.C. Rowe, P.J. Sheskey, S.C.Owen (Eds.), Handbook of Pharmaceutical Excipients, Pharmaceutical press. 2006: 545-550.
- 91) S.C. Owen, P.J. Weller, Propylene glycol, in: R.C. Rowe, P.J. Sheskey, S.C. Owen (Eds.), Handbook of Pharmaceutical Excipients, Pharmaceutical press. 2006: 624-626.
- 92) A. Palmieri, Triacetin, in: R.C. Rowe, P.J. Sheskey, S.C. Owen (Eds.), Handbook of Pharmaceutical Excipients, Pharmaceutical press. 2006: 790-791.
- 93) S.W. Kennedy, Tributyl citrate, in: R.C. Rowe, P.J. Sheskey, S.C.Owen (Eds.), Handbook of Pharmaceutical Excipients, Pharmaceutical press. 2006: 792-793.
- 94) W. Kennedy, Triethyl citrate, in: R.C. Rowe, P.J. Sheskey, S.C. Owen (Eds.), Handbook of Pharmaceutical Excipients, Pharmaceutical press. 2006: 796-797.
- 95) R.C. Rowe, S.F. Forse, The effect of polymermolecularweight on the incidence of film cracking and splitting on film coated tablets, J. Pharm. Pharmacol. 1980;32(8) 583-584.
- 96) R.C. Rowe, S.F. Forse, The effect of film thickness on the incidence of the defect bridging of intagliations on film coated tablets, J. Pharm. Pharmacol. 1980;32(9) 647-648.
- 97) R.C. Rowe, S.F. Forse, The effect of plasticizer type and concentration on the incidence of bridging of intagliations on film-coated tablets, J.Pharm.Pharmacol.1981;33 (3)174-175.
- 98) P. Singh, J.K. Guillory, T.D. Sokoloski, L.Z. Benet, V.N. Bhatia, Effect of inert tablet ingredients on drug absorption I. Effect of polyethylene glycol

- 4000 on the intestinal absorption of four barbiturates, *J. Pharm. Sci.* 55 (1) (1966) 63–68.
- 99) G.L. Brown, Formation of films from polymer dispersions, *J. Polym. Sci.* 1956;22 (102): 423–434.
- 100) Sakellariou, R.C. Rowe, Interactions in cellulose derivative films for oral drug delivery, *Prog. Polym. Sci.* 1995; 20:889–942.
- 101) N. Cao, X. Yang, Y. Fu, Effects of various plasticizers on mechanical and water vapor barrier properties of gelatin films, *Food Hydrocolloids.* 2009;23:729–735.
- 102) C.Wu, J.W. McGinity, Influence of ibuprofen as a solid-state plasticizer in Eudragit RS 30 D on the physicochemical properties.
- 103) J.A. Mennella, G.K. Beauchamp, Optimizing oral medications for children, *Clin. Ther.* 2008;30 (11): 2120–2132.
- 104) F. Hutteau, M. Mathlouthi, M.O. Portmann, D. Kilcast, Physicochemical and psychophysical characteristics of binary mixtures of bulk and intense sweeteners, *Food Chem.* 1998; 63 (1) :9–16.
- 105) I. Prakash, G.E. DuBois, J.F. Clos, K.L. Wilkens, L.E. Fosdick, Development of rebiana, a natural, non-caloric sweetener, *Food Chem. Toxicol.* 2008;46 :S75–S82.
- 106) K. Israel, M.Leo. Salivary stimulant. US Patent 4820506, april 11,1989.
- 107) S.Sau-hung, S Robert, D Lori. Fast dissolving orally consumable films, US Patent 6,596,298, July 22, 2003.
- 108) G. Sward, Drying time, in: G. Sward (Ed.), *Paint Testing Manual— physical and chemical examination of paints varnishes lacquers, and colors*, 13th Ed., American Society for Testing and Materials. 268.
- 109) L. Felton, P. O'Donnell, J. McGinity, Mechanical properties of polymeric films prepared from aqueous dispersions, in: *Aqueous polymeric coatings for pharmaceutical dosage forms*, 3rd edition, J. McGinity, L. Felton (Eds), Vol. 176, *Drugs and the pharmaceutical sciences*, 108.
- 110) S.V. Fulzele, P.M. Sattuwar, A.K. Dorle, Polymerized rosin: novel film forming polymer for drug delivery, *Int J Pharm.* 2002;249 :175–184.
- 111) American Standard of Testing and Materials, ASTM D1004 – 08 Standard Test Method for Tear Resistance (Graves Tear) of Plastic Film and Sheeting.
- 112) A.J. Shinde, K.C. Garala, H.N. More, Development and characterization of transdermal therapeutics system of tramadol hydrochloride, *Asian J. Pharm.* 2008;2 (4):265–269.
- 113) V. Anand, M. Kataria, V. Kukkar, V. Saharan, P.K. Choudhury, The latest trends in the taste assessment of pharmaceuticals, *Drug Discovery Today.* 2007; 12:257–265.

